A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis

@article{Yonghong2008ARC,
  title={A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis},
  author={Huang Yonghong and Tu Sheng-hao and Liu Peilin},
  journal={Journal of Tongji Medical University},
  year={2008},
  volume={21},
  pages={72-74}
}
SummaryThe efficacy and safety of leflunomide (LEF) in the treatment of rheumatoid arthritis (RA) were evaluated and the comparison with methotrexate’s (MTX’s) was performed in a 12-week, single-blind, randomized, parallel trial for treating 81 patients with RA. There were 56 cases in LEF group and 25 cases in MTX group. The dose of LEF was 20 mg per day and MTX 15 mg per week. All patients took oxaproxin simultaneously at the 4th to 6th week after the trail. The results showed that the general… Expand
3 Citations
Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
TLDR
Results indicated that low dose LEF monotherapy was not inferior to the combination therapy, and when the dose of LEF was less than 40 mg/day, no significant difference was observed between low and high doses. Expand
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
TLDR
Starting on methotrexate 15mg/week orally, escalating with 5 mg/month to 25–30 mg/week, or the highest tolerable dose, with a subsequent switch to subcutaneous administration in the case of an insufficient response, seems to be the optimal evidence-based dosing and routing recommendation for metotrexate in RA. Expand
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.
TLDR
This data indicates that methotrexate monotherapy or in combination with any currently used conventional synthetic DMARD , biologic DMARDs, or tofacitinib combinations for rheumatoid arthritis in patients naïve to or with an inadequate response (IR) to metotrexate is a viable treatment option. Expand

References

SHOWING 1-10 OF 21 REFERENCES
Approaches to the management of systemic lupus erythematosus.
  • V. Strand
  • Medicine
  • Current opinion in rheumatology
  • 1997
TLDR
A variety of biologic and pharmaceutical agents offer promise as potential therapies for systemic lupus erythematosus, and development of these products will benefit from active involvement of rheumatologists and efforts to develop international consensus regarding trial methodology and outcome measures. Expand
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 controlExpand
Estradiol Protects against Ischemic Injury
  • D. Dubal, M. Kashon, +4 authors P. Wise
  • Medicine, Chemistry
  • Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 1998
TLDR
The finding that estradiol pretreatment reduces injury demonstrates that physiologic levels of Estradiol can protect against neurodegeneration. Expand
Revised criteria for the classification of rheumatoid arthritis.
The Bulletin on the Rheumatic Diseases has published all of the classification criteria for the rheumatic diseases to date. These new revised classification criteria for rheumatoid arthritis are veryExpand
Neuroprotection by Estrogens in a Mouse Model of Focal Cerebral Ischemia and in Cultured Neurons: Evidence for a Receptor-Independent Antioxidative Mechanism
  • C. Culmsee, H. Vedder, +5 authors J. Krieglstein
  • Medicine, Chemistry
  • Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 1999
TLDR
It is concluded that estrogens protect neurons against damage by radical scavenging rather than through estrogen receptor activation, and this effect was influenced by the estrogen receptor antagonist tamoxifen. Expand
Estrogen diminishes postischemic hydroxyl radical production.
TLDR
It is shown that administration of conjugated equine estrogen to fully anesthetized dogs abolishes the burst of ⋅ OH radicals typically produced on reperfusion of the myocardium, indicating that estrogen might attenuate reperfusions-induced ventricular arrhythmias by virtue of its antioxidant properties, suggesting a novel cardioprotective effect of the hormone. Expand
Estrogen and microglia: A regulatory system that affects the brain.
TLDR
This work presents evidence for the presence of estrogen receptor-beta (ERbeta) in rat microglial cells and believes that many of the immune and nonimmune regulatory functions of microglia in the brain are influenced directly by estrogen via expression and secretion of cytokines, and growth factors by themicroglia. Expand
Glucose and lactate metabolism after severe human head injury: influence of excitatory neurotransmitters and injury type.
TLDR
It is demonstrated that glutamate clearly influences the release of lactate following injury, supporting the hypothesis that glutamate "drives" glycolysis in astrocytes and indicating an effect of glutamate upon glucose uptake by cells which differs according to the type of injury. Expand
Excitatory Amino Acid Receptors and Their Role in Epilepsy and Cerebral Ischemia
  • B. Meldrum
  • Biology, Medicine
  • Annals of the New York Academy of Sciences
  • 1995
TLDR
Astrocytes show a calcium-dependent release of glutamate that can be triggered by bradykinin and other agents incrcasing intraccllular calcium concentration in astrocytes, and glia can both respond to increases in extracellular glutamate and induce neuronal responses (via NMDA receptors6) to glutamate. Expand
Acute brain injury, NMDA receptors, and hydrogen ions: observations in cortical cell cultures.
TLDR
Demonstration that a given pharmacological manipulation is neuroprotective in such cultures establishes that a beneficial effect can be produced directly on brain parenchyma, without involvement of systemic metabolism or alterations in blood flow. Expand
...
1
2
3
...